Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: A systematic review

Anjali V. Sheahan; Andrew V. Biankin; Christopher R. Parish; Levon M. Khachigian

doi:10.18632/oncotarget.25085

Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: A systematic review

Anjali V. Sheahan, Andrew V. Biankin, Christopher R. Parish, Levon M. Khachigian^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

39 Citations (Scopus)

Abstract

Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with unresectable (locally advanced or metastatic) tumors. We discuss a range of studies that employed FOLFIRINOX, the gemcitabine + nab-paclitaxel combination and studies that used molecularly-targeted therapy. Major areas of focus have been dual targeting of EGFR and VEGFR, immunotherapy or a multimodal approach - combining chemotherapy with radiotherapy. We also point out the need for molecular selection for low prevalence subtypes. Key insights sourced from these pivotal trials should improve clinical outcomes for this devastating cancer.

Original language	English
Pages (from-to)	21613-21627
Number of pages	15
Journal	Oncotarget
Volume	9
Issue number	30
DOIs	https://doi.org/10.18632/oncotarget.25085
Publication status	Published - 20 Apr 2018

Access to Document

10.18632/oncotarget.25085

Cite this

@article{a86b7c98211d4a36ad02a0ed3251f3b5,

title = "Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: A systematic review",

abstract = "Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with unresectable (locally advanced or metastatic) tumors. We discuss a range of studies that employed FOLFIRINOX, the gemcitabine + nab-paclitaxel combination and studies that used molecularly-targeted therapy. Major areas of focus have been dual targeting of EGFR and VEGFR, immunotherapy or a multimodal approach - combining chemotherapy with radiotherapy. We also point out the need for molecular selection for low prevalence subtypes. Key insights sourced from these pivotal trials should improve clinical outcomes for this devastating cancer.",

keywords = "Bibliometric analysis, Clinical trials, Pancreatic cancer",

author = "Sheahan, {Anjali V.} and Biankin, {Andrew V.} and Parish, {Christopher R.} and Khachigian, {Levon M.}",

note = "Publisher Copyright: {\textcopyright} Sheahan et al.",

year = "2018",

month = apr,

day = "20",

doi = "10.18632/oncotarget.25085",

language = "English",

volume = "9",

pages = "21613--21627",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "30",

}

TY - JOUR

T1 - Targeted therapies in the management of locally advanced and metastatic pancreatic cancer

T2 - A systematic review

AU - Sheahan, Anjali V.

AU - Biankin, Andrew V.

AU - Parish, Christopher R.

AU - Khachigian, Levon M.

N1 - Publisher Copyright: © Sheahan et al.

PY - 2018/4/20

Y1 - 2018/4/20

N2 - Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with unresectable (locally advanced or metastatic) tumors. We discuss a range of studies that employed FOLFIRINOX, the gemcitabine + nab-paclitaxel combination and studies that used molecularly-targeted therapy. Major areas of focus have been dual targeting of EGFR and VEGFR, immunotherapy or a multimodal approach - combining chemotherapy with radiotherapy. We also point out the need for molecular selection for low prevalence subtypes. Key insights sourced from these pivotal trials should improve clinical outcomes for this devastating cancer.

AB - Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with unresectable (locally advanced or metastatic) tumors. We discuss a range of studies that employed FOLFIRINOX, the gemcitabine + nab-paclitaxel combination and studies that used molecularly-targeted therapy. Major areas of focus have been dual targeting of EGFR and VEGFR, immunotherapy or a multimodal approach - combining chemotherapy with radiotherapy. We also point out the need for molecular selection for low prevalence subtypes. Key insights sourced from these pivotal trials should improve clinical outcomes for this devastating cancer.

KW - Bibliometric analysis

KW - Clinical trials

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85045830079&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.25085

DO - 10.18632/oncotarget.25085

M3 - Review article

SN - 1949-2553

VL - 9

SP - 21613

EP - 21627

JO - Oncotarget

JF - Oncotarget

IS - 30

ER -

Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: A systematic review

Abstract

Access to Document

Other files and links

Fingerprint

Cite this